Chien Cheng Lin
Executive VP, Chief Strategy Officer & Executive DirectorMr. Chien Cheng Lin, also known as George, J.D., has been Executive Vice President at Hua Medicine (Shanghai) Ltd. since December 22, 2017 and has been its Chief Strategy Officer since March 30, 2023 and served as its Executive Director since May 11, 2018 until 2024. He was Chief Financial Officer at Hua Medicine (Shanghai) Ltd. since December 22, 2017 until March 30, 2023. He served as an Independent Non-Executive Director of Shanghai Bio-heart Biological Technology Co., Ltd., since November 24, 2020 until June 26, 2023. Mr. Lin has investment banking and legal experience working with numerous private and public companies globally. Prior to joining Hua, he was Asia Pacific Head of Consumer, Retail and Healthcare Investment Banking and head of investment banking coverage for both Hong Kong and Taiwan for Bank of America Merrill Lynch based in Hong Kong. As an investment banker and corporate lawyer focused on healthcare, retail and the consumer sectors, Mr. Lin was most recently based in Hong Kong. His experience entails IPOs, debt and equity financings and M&As for leading companies in Asia, the United States and Europe. Mr. Lin received a Bachelor of Sciences degree in Biological Sciences from the University of California at Davis in June 1992 and a Juris Doctor degree from The University of Chicago Law School in June 1995.
Positions
- Company NameHua Medicine (Shanghai) Ltd.Stock Code02552PositionExecutive VP, Chief Strategy Officer & Executive DirectorColleagues
- LCLi ChenFounder, CEO, Member of Portfolio Advisory Board & Executive Director
- RTRobert Taylor NelsenNon-Executive Chairman
- YZYi ZhangSenior VP of Pharma Development, Chief Medical Officer – China and Executive Director
- FTFuxing TangCTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA
- CLChanghong LiChief Scientific Officer
- WRWilliam Robert KellerIndependent Non-Executive Director
